HUE053156T2 - Vegyületek agyi áttétek kezelésében történõ alkalmazásra ERBB2+ emlõrákos betegeknél - Google Patents

Vegyületek agyi áttétek kezelésében történõ alkalmazásra ERBB2+ emlõrákos betegeknél

Info

Publication number
HUE053156T2
HUE053156T2 HUE18162971A HUE18162971A HUE053156T2 HU E053156 T2 HUE053156 T2 HU E053156T2 HU E18162971 A HUE18162971 A HU E18162971A HU E18162971 A HUE18162971 A HU E18162971A HU E053156 T2 HUE053156 T2 HU E053156T2
Authority
HU
Hungary
Prior art keywords
erbb2
patients
compounds
treatment
breast cancer
Prior art date
Application number
HUE18162971A
Other languages
English (en)
Hungarian (hu)
Inventor
Patrice A Lee
Shannon L Winski
Kevin Koch
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48048296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE053156(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of HUE053156T2 publication Critical patent/HUE053156T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
HUE18162971A 2012-03-23 2013-03-25 Vegyületek agyi áttétek kezelésében történõ alkalmazásra ERBB2+ emlõrákos betegeknél HUE053156T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261615082P 2012-03-23 2012-03-23

Publications (1)

Publication Number Publication Date
HUE053156T2 true HUE053156T2 (hu) 2021-06-28

Family

ID=48048296

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE18162971A HUE053156T2 (hu) 2012-03-23 2013-03-25 Vegyületek agyi áttétek kezelésében történõ alkalmazásra ERBB2+ emlõrákos betegeknél
HUE13714497A HUE037966T2 (hu) 2012-03-23 2013-03-25 Amorf szilárd diszperzió agyrák kezelésében történõ alkalmazásra

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE13714497A HUE037966T2 (hu) 2012-03-23 2013-03-25 Amorf szilárd diszperzió agyrák kezelésében történõ alkalmazásra

Country Status (30)

Country Link
US (3) US20150110780A1 (cg-RX-API-DMAC7.html)
EP (4) EP3400943B1 (cg-RX-API-DMAC7.html)
JP (6) JP2015514075A (cg-RX-API-DMAC7.html)
KR (3) KR102160462B1 (cg-RX-API-DMAC7.html)
CN (2) CN109223791A (cg-RX-API-DMAC7.html)
AU (4) AU2013234921A1 (cg-RX-API-DMAC7.html)
CA (1) CA2867723C (cg-RX-API-DMAC7.html)
CL (1) CL2014002497A1 (cg-RX-API-DMAC7.html)
CO (1) CO7071139A2 (cg-RX-API-DMAC7.html)
CY (2) CY1120204T1 (cg-RX-API-DMAC7.html)
DK (2) DK2827900T3 (cg-RX-API-DMAC7.html)
ES (2) ES2673165T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20180659T1 (cg-RX-API-DMAC7.html)
HU (2) HUE053156T2 (cg-RX-API-DMAC7.html)
IL (3) IL234627B (cg-RX-API-DMAC7.html)
LT (1) LT2827900T (cg-RX-API-DMAC7.html)
MX (1) MX354024B (cg-RX-API-DMAC7.html)
MY (2) MY174883A (cg-RX-API-DMAC7.html)
NZ (4) NZ724544A (cg-RX-API-DMAC7.html)
PH (2) PH12021550360A1 (cg-RX-API-DMAC7.html)
PL (2) PL2827900T3 (cg-RX-API-DMAC7.html)
PT (2) PT2827900T (cg-RX-API-DMAC7.html)
RS (1) RS57140B1 (cg-RX-API-DMAC7.html)
RU (2) RU2018138976A (cg-RX-API-DMAC7.html)
SG (1) SG11201405954YA (cg-RX-API-DMAC7.html)
SI (2) SI2827900T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201800251T1 (cg-RX-API-DMAC7.html)
TR (1) TR201808450T4 (cg-RX-API-DMAC7.html)
UA (1) UA122044C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013142875A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga
WO2018165015A1 (en) * 2017-03-09 2018-09-13 The Board Of Trustees Of The Leland Stanford Junior University Treatment of pediatric brain tumors with targeting of cd47 pathway
EP3615067A1 (en) 2017-04-28 2020-03-04 Seattle Genetics, Inc. Treatment of her2 positive cancers
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
CN112566665A (zh) * 2018-04-09 2021-03-26 莫舍·吉拉迪 用TTFields和Aurora激酶抑制剂治疗肿瘤
CN109942576B (zh) * 2019-03-07 2020-09-11 上海工程技术大学 Irbinitinib及中间体的制备方法
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
CN111825604A (zh) * 2019-04-16 2020-10-27 宁波药腾医药科技有限公司 一种图卡替尼及其中间产物的合成方法
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
US20250387380A1 (en) * 2019-12-30 2025-12-25 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH690163A5 (fr) * 1995-07-28 2000-05-31 Symphar Sa Dérivés gem-diphosphonates substitués utiles en tant qu'agents anti-cancers.
US6350786B1 (en) * 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
RU2255765C2 (ru) * 2000-01-21 2005-07-10 Чилдренз Хоспитал Лос-Анджелес Способ ингибирования роста опухолей головного мозга с помощью отобранных антагонистов интегринов
US20020137731A1 (en) 2000-05-30 2002-09-26 Gewirtz David A. Combination of radiation and vitamin D3 analogs for the treatment of cancer
JP4828421B2 (ja) 2003-08-14 2011-11-30 アレイ バイオファーマ、インコーポレイテッド 受容体チロシンキナーゼ阻害剤としてのキナゾリン誘導体
BRPI0511754A (pt) 2004-06-03 2008-01-02 Smithkline Beechman Cork Ltd uso de um composto ou sais ou solvatos do mesmo
CN1989112A (zh) * 2004-06-03 2007-06-27 史密丝克莱恩比彻姆(科克)有限公司 癌症治疗方法
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
CA2637166A1 (en) 2006-01-31 2007-10-18 Novartis Ag Il-17 antagonistic antibodies for treating cancer
US20120052061A1 (en) * 2007-09-24 2012-03-01 Tragara Pharmaceuticals Inc. Therapies for treating cancer using combinations of cox-2 inhibitors and anti-her2(erbb2) antibodies or combinations of cox-2 inhibitors and her2(erbb2) receptor tyrosine kinase inhibitors
NZ587706A (en) * 2008-03-18 2012-12-21 Genentech Inc Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
KR102000312B1 (ko) 2011-10-14 2019-07-15 어레이 바이오파마 인크. Erb2 (her2) 저해제의 고체 분산물
US9168254B2 (en) * 2011-10-14 2015-10-27 Array Biopharma Inc. Polymorphs of ARRY-380, a selective HER 2 inhibitor and pharmaceutical compositions containing them
RS57140B1 (sr) 2012-03-23 2018-07-31 Array Biopharma Inc Amorfna čvrsta disperzija za korišćenje u lečenju raka mozga

Also Published As

Publication number Publication date
KR20140139009A (ko) 2014-12-04
MY174883A (en) 2020-05-20
RS57140B1 (sr) 2018-07-31
IL269205A (en) 2019-11-28
PH12021550360A1 (en) 2023-04-03
EP3400943A1 (en) 2018-11-14
RU2672575C2 (ru) 2018-11-16
EP2827900A1 (en) 2015-01-28
US20190255051A1 (en) 2019-08-22
HK1206276A1 (en) 2016-01-08
AU2019203618A1 (en) 2019-06-13
PT2827900T (pt) 2018-06-14
DK2827900T3 (en) 2018-05-07
CA2867723A1 (en) 2013-09-26
EP4252855A3 (en) 2023-11-15
SI3400943T1 (sl) 2021-03-31
MX2014011437A (es) 2014-11-10
JP2015514075A (ja) 2015-05-18
LT2827900T (lt) 2018-05-10
CY1120204T1 (el) 2018-12-12
DK3400943T3 (da) 2021-02-08
AU2017272232C1 (en) 2019-08-15
CN104203279B (zh) 2018-10-30
JP2022190126A (ja) 2022-12-22
NZ630843A (en) 2017-01-27
CO7071139A2 (es) 2014-09-30
PT3400943T (pt) 2021-02-02
AU2017272232B2 (en) 2019-02-28
CA2867723C (en) 2022-11-08
KR20210131426A (ko) 2021-11-02
EP3400943B1 (en) 2020-12-02
HRP20180659T1 (hr) 2018-06-01
WO2013142875A1 (en) 2013-09-26
NZ724544A (en) 2018-05-25
MY202114A (en) 2024-04-04
PL2827900T3 (pl) 2018-08-31
CY1123837T1 (el) 2022-05-27
US20150110780A1 (en) 2015-04-23
KR102160462B1 (ko) 2020-09-28
AU2021261849A1 (en) 2021-12-02
NZ741615A (en) 2019-10-25
RU2018138976A3 (cg-RX-API-DMAC7.html) 2022-04-08
RU2018138976A (ru) 2018-12-06
ES2673165T3 (es) 2018-06-20
CL2014002497A1 (es) 2014-11-14
KR102317166B1 (ko) 2021-10-26
AU2017272232A1 (en) 2018-01-04
JP2024019526A (ja) 2024-02-09
KR102490961B1 (ko) 2023-01-19
NZ756264A (en) 2022-09-30
JP2017141302A (ja) 2017-08-17
RU2014142700A (ru) 2016-05-20
ES2855142T3 (es) 2021-09-23
IL261659A (en) 2018-10-31
US20230190749A1 (en) 2023-06-22
EP2827900B1 (en) 2018-03-21
SG11201405954YA (en) 2014-10-30
SMT201800251T1 (it) 2018-07-17
HUE037966T2 (hu) 2018-09-28
US11504370B2 (en) 2022-11-22
JP6898960B2 (ja) 2021-07-07
JP7404485B2 (ja) 2023-12-25
CN104203279A (zh) 2014-12-10
PL3400943T3 (pl) 2021-06-14
CN109223791A (zh) 2019-01-18
PH12014502032A1 (en) 2014-11-24
UA122044C2 (uk) 2020-09-10
AU2019203618B2 (en) 2021-08-05
KR20200115656A (ko) 2020-10-07
EP3842044A1 (en) 2021-06-30
MX354024B (es) 2018-02-08
JP2021178820A (ja) 2021-11-18
SI2827900T1 (en) 2018-06-29
TR201808450T4 (tr) 2018-07-23
JP2019081792A (ja) 2019-05-30
AU2013234921A1 (en) 2014-10-02
IL269205B (en) 2020-06-30
EP4252855A2 (en) 2023-10-04
IL234627B (en) 2018-10-31

Similar Documents

Publication Publication Date Title
IL289300A (en) Combination therapy for treating cancer
IL268094B (en) History of heterocyclic compounds for use in the treatment of lung cancer
IL239007B (en) Eribulin for use in the treatment of breast cancer
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
SI3400943T1 (sl) Spojine za uporabo pri zdravljenju možganskih metastaz pri bolniku z ErbB2+ rakom dojke
PL2959005T3 (pl) Zastosowanie medyczne dotyczące wydłużania telomerów
EP3008214A4 (en) Non-invasive blood based monitoring of genomic alterations in cancer
DK3010519T3 (en) Oncolytic adenovirus for use in a treatment of brain cancer
SG11201501653RA (en) Methods for the treatment of locally advanced breast cancer
HUE040524T2 (hu) Mellrák kezelése
PT2802606T (pt) Melhoramento do transporte de moléculas terapêuticas através da barreira hematoencefálica
HRP20190046T1 (hr) Kombinirana terapija za liječenje raka
HRP20180670T1 (hr) Novi postupak dobivanja spojeva namijenjenih upotrebi u liječenju raka
LT2914254T (lt) Kombinacinės terapijos chemoresistencinių vėžių gydymui
PL2742356T3 (pl) Środki prognostyczne w leczeniu nowotworów
DK2802351T3 (da) Midler til behandling af triple-negativ brystkræft
PL3071192T3 (pl) Związek kurkufenol do zastosowania w leczeniu nowotworu
SI2892925T1 (sl) Kombinacijsko zdravljenje raka
EP2925361A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF HER2-POSITIVE CARCINOMA
FI20126281L (fi) Temotsolomidin polymeeripartikkelipohjainen annosmuoto pahanlaatuisten kasvainten hoitoon
IL246065A0 (en) Valiprib in combination with carboplatin for the treatment of triple negative breast cancer
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201222950D0 (en) Combination treatment of cancer
GB201222949D0 (en) Combination Treatment of Cancer